FBIO Stock Forecast: Fortress Biotech, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Fortress Biotech, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Fortress Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Momentum (40): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
FBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | $17 |
| 21 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Mar 2025 | Roth MKM | Reiterates | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 16 May 2024 | Roth MKM | Reiterates | Buy | — |
| 19 Mar 2024 | Alliance Global Partners | Initiates | Buy | — |
| 15 Mar 2024 | Roth MKM | Reinstates | Buy | $10 |
| 29 Nov 2023 | Roth MKM | Maintains | Buy | — |
| 15 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | $5.00 |
| 16 May 2023 | Cantor Fitzgerald | Maintains | Overweight | $6.00 → $5.00 |
| 6 Apr 2023 | Benchmark | Reiterates | Speculative Buy | $5.00 |
| 4 Aug 2022 | Ladenburg Thalmann | Initiates | Buy | $6.00 |
| 14 July 2022 | B. Riley Securities | Maintains | Buy | $8.00 → $6.00 |
| 20 Apr 2021 | Roth Capital | Maintains | Buy | $4.50 → $5.00 |
| 13 Oct 2020 | Roth Capital | Maintains | Buy | $5.00 → $4.75 |
| 12 Oct 2020 | HC Wainwright & Co. | Maintains | Buy | $11 → $10 |
| 2 Oct 2020 | Benchmark | Initiates | Buy | — |
| 13 Mar 2020 | B. Riley FBR | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FBIO.
This page is one stock. Monday covers all of them.
FBIO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
FBIO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Fortress Biotech, Inc. returned −24.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.8×
- Price / sales
- 0.9×
- Price / book
- 0.4×
- EV / EBITDA
- —
Cheaper than 93% of US stocks
Cheaper than 68% of US stocks
Cheaper than 89% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 67.2%
- Operating margin
- −42.8%
- Net margin
- —
Higher than 80% of US stocks
Higher than 19% of US stocks
- Return on equity
- 102.5%
- Return on assets
- −8.1%
- Dividend yield
- —
Higher than 96% of US stocks
Higher than 28% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Fortress Biotech, Inc. has a market value of $64.1M.
Revenue in the twelve months to 30 June 2026: $68.5M. The latest quarter grew 14.0% year on year.
Net income over the same four quarters: $141.2M, a 206.2% net margin.
Free cash flow in the twelve months to 30 June 2026: $125.8M.
Fortress Biotech, Inc. spent $14.3M on share buybacks and $473K on dividends in the twelve months to 30 June 2026.
Trailing P/E: 0.8×.
Fortress Biotech, Inc. employs 78 people — $878K of revenue per employee.
Data provided by Twelve Data
FBIO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at FBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Fortress Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about FBIO
What is the FBIO stock price forecast for 2026-2027?
The median 12-month analyst price target for Fortress Biotech, Inc. is $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FBIO stock a buy right now?
Of the 1 analyst covering Fortress Biotech, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fortress Biotech, Inc. 87 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FBIO?
As at 21 Nov 2026, Fortress Biotech, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
Will FBIO stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $5, and Ticker Nerd's factor model ranks Fortress Biotech, Inc. 87 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FBIO stock forecast for 2030?
No analyst covering Fortress Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.
How has FBIO stock performed over the past year?
Fortress Biotech, Inc. returned -24.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biotechnology products. Fortress Biotech operates through two core areas: dermatology product sales and pharmaceutical and biotechnology product development.
About Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biotechnology products. Fortress Biotech operates through two core areas: dermatology product sales and pharmaceutical and biotechnology product development. Its commercial portfolio includes prescription and specialty dermatology therapies used for conditions such as acne, rosacea, hyperhidrosis, and other skin-related disorders, alongside wound-care and supportive treatment products. The company also advances a broader pipeline and portfolio of assets through its subsidiary and partner network, supporting programs in areas such as rare diseases and oncology. Fortress Biotech plays a role in the healthcare market by combining product sales with asset development, royalties, and other collaboration-based revenue streams. Headquartered in Bay Harbor Islands, Florida, Fortress Biotech serves a range of medical professionals and patients across the United States and international markets.
CEO Dr. Lindsay Allan Rosenwald M.D. · 78 employees · United States · https://www.fortressbiotech.com